The Importance of Testing for BRCA Mutations in BC
Multiple guidelines recommend germline BRCA1/2 mutation testing in certain patients with BC, including:
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1
- ASCO Guidelines2
- SGO Guidelines3
- ASBS Guidelines4
BRCA mutation testing can provide important insights for you and your patients

BRCA mutations are associated with a higher risk of developing certain cancers, including BC and OC.5,6


The role of BRCA mutations in cancer risk


In healthy cells, BRCA proteins play a critical role in the repair of DNA double-strand breaks.9


Mutations in BRCA may prevent the proper repair of DNA or cause it to be repaired via more error-prone mechanisms.9


This may cause DNA damage to accumulate and eventually lead to the development of cancer.10
If a BRCA mutation is detected in someone who does not have cancer, they have the opportunity to6:
test
- Undergo more intensive screening for BRCA mutation–associated cancers
- Take preventative measures, such as prophylactic surgery

BRCA mutations may provide information about the course of your patient's disease.11,12

Knowing your patient's BRCA mutation status may aid in the development of a comprehensive treatment plan.6,13-15
Role of PARP inhibition in certain cancers with BRCA mutations


PARP plays an integral role in repairing certain types of DNA damage, including single-strand DNA breaks.16


Inhibition of PARP can disrupt this DNA repair.16


Because both BRCA and PARP are important for repairing DNA, inhibiting PARP in a cell that already has a BRCA mutation can lead to cancer cell death.10

In BC, germline BRCA mutations can determine eligibility for certain treatments.17
Testing can inform treatment decisions and, therefore, should take place as early as possible for appropriate patients.18
Testing can inform treatment decisions and, therefore, should take place as early as possible for appropriate patients.18
Watch to learn how BRCA mutations can drive the pathogenesis of BC.
ASBS, American Society of Breast Surgeons; ASCO, American Society of Clinical Oncology; BC, breast cancer; BRCA, breast cancer susceptibility gene; NCCN, National Comprehensive Cancer Network; OC, ovarian cancer; PARP, poly ADP-ribose polymerase; SGO, Society of Gynecologic Oncology.
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V3.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 16, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Lu KH et al. J Clin Oncol. 2014;32(8):833-840. 3. Lancaster JM et al; SGO Clinical Practice Committee. Gynecol Oncol. 2015;136(1):3-7. 4. The American Society of Breast Surgeons. https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf. Accessed May 28, 2019. 5. Miller-Samuel S et al. Semin Oncol. 2011;38(4):469-480. 6. Larsen MJ et al. Breast Cancer (Auckl). 2014;8:145-155. 7. National Cancer Institute. https://seer.cancer.gov/statfacts/html/breast.html. Accessed May 30, 2019. 8. Kuchenbaecker KB et al; BRCA1 and BRCA2 Cohort Consortium. JAMA. 2017;317(23):2402-2416. 9. Gudmundsdottir K et al. Oncogene. 2006;25(43):5864-5874. 10. McLornan DP et al. N Engl J Med. 2014;371(18):1725-1735. 11. van den Broek AJ et al. PLoS One. 2015;10(3):e0120189. 12. Goodwin PJ et al. J Clin Oncol. 2012;30(1):19-26. 13. Robson M et al. N Engl J Med. 2017;337(6):523-533. 14. Litton JK et al. N Engl J Med. 2018;379(8):753-763. 15. Fong PC et al. N Engl J Med. 2009;361(2):123-134. 16. O’Sullivan CC et al. Front Oncol. 2014;4:42. 17. FDA. https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm. Accessed September 5, 2018. 18. Smith KL et al. Cancer J. 2011;17(6):492-499.
You are leaving this site
This link will take you to a site maintained by a third party who is solely responsible for its contents.
AstraZeneca provides this link as a service to Web site visitors. AstraZeneca is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit.
You are leaving this site
This link will take you to a site maintained by a third party who is solely responsible for its contents.
AstraZeneca provides this link as a service to Web site visitors. AstraZeneca is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit.